Datapoint: FDA Delays New Leqembi Launch
The launch of a new version of Eisai and Biogen’s Leqembi (lecanemab) has been delayed, with the FDA requesting additional information about the Alzheimer’s drug. The FDA wants more data about the effectiveness of subcutaneous injection relative to infusion, Leqembi’s current form of administration. Currently, Leqembi must be infused onsite in a clinical setting every two weeks. The drugmakers hope that a switch to biweekly injections will reduce the burden of administration for practitioners and speed adoption of the drug, which Eisai admits has been slower than hoped. For the treatment of Alzheimer’s disease, 38% of all insured lives have covered or better access to Leqembi under the medical benefit.
SOURCE: MMIT Analytics, as of 4/16/24